Authors: Farlow, MR Hake, A Messina, J Hartman, R Veach, J Anand, R

Citation: Mr. Farlow et al., Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression, ARCH NEUROL, 58(3), 2001, pp. 417-422

Authors: Kumar, V Anand, R Messina, J Hartman, R Veach, J

Citation: V. Kumar et al., An efficacy and safety analysis of Exelon (R) in Alzheimer's disease patients with concurrent vascular risk factors, EUR J NEUR, 7(2), 2000, pp. 159-169

Authors: Grossberg, GT Stahelin, HB Messina, JC Anand, R Veach, J

Citation: Gt. Grossberg et al., Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications, INT J GER P, 15(3), 2000, pp. 242-247

Authors: Farlow, M Anand, R Messina, J Hartman, R Veach, J

Citation: M. Farlow et al., A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease, EUR NEUROL, 44(4), 2000, pp. 236-241